Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

y solid growth of key pharmaceutical brands and vaccines, strong sales in Emerging Markets and recent acquisitions. Multaq has just been launched in the U.S. in July. The strong progression of our earnings has led us to raise our guidance for 2009 to EPS(4) growth of around 10%. Since the beginning of the year, we have launched a new R&D approach to increase innovation, we have strengthened our growth platforms through acquisitions, and we are moving forward with the transformation of our company. Those achievements constitute another step toward our vision of becoming a leading diversified global healthcare company, with a sustainable growth profile by 2013".

(3) Closing expected in Q3 2009 (4) Adjusted EPS excluding selected items, at constant exchange rates and barring major adverse events

2009 second-quarter and first-half net sales

Unless otherwise indicated, all sales growth figures in this press release are stated at constant exchange rates.

In the second quarter of 2009, sanofi-aventis generated net sales of euro 7,438 million, an increase of 11.2% on a reported basis. Exchange rate movements had a favorable effect of 4.7 points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies. At constant exchange rates, and after taking account of changes in structure (in particular the consolidation of Zentiva), net sales rose by 6.5%. Excluding changes in structure and at constant exchange rates, second-quarter net sales growth was 3.7%.

In the first half of 2009, sanofi-aventis posted net sales of euro 14,545 million, an increase of 6.7%. Exchange rate movements, primarily the appreciation of the U.S. dollar against the euro, had a favorable effect of 3.6 points. At constant exchange rates, and after taking account of changes in stru
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... May 25, 2011 /PRNewswire/ -- Vermillion, ... today announced that the United States Patent and Trademark Office ... entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s Disease." ... as well as combinations that include these biomarkers. ...
... 2011 VIVUS, Inc. (NASDAQ: ... 3, placebo-controlled clinical trial of the investigational drug avanafil ... following a radical prostatectomy. The study (REVIVE-RP, TA-303) met ... erectile function as measured by the Sexual Encounter Profile ...
... 24, 2011 Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – today announced ... rule 5550(a)(2), which concerns minimum bid price listing ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 2VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 4VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 5Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... wildlife while feeding a world population predicted to ... holistic approach to conservation that considers human-altered landscapes ... Wildlife and the natural habitat that supports it ... world where at least three-quarters of the land ... rest is vulnerable to human-caused impacts such as ...
(Date:4/18/2014)... Ancient DNA adds a twist to the story of how ... published April 21 in the journal Proceedings of the ... bones of chickens that lived 200-2300 years ago in Europe, ... chickens may have looked far different from the chickens we ... traits we associate with modern domestic chickens -- such as ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2
... a well known cell surface protein inhibited prostate cancer ... disease that did not respond to hormone therapy, according ... of Urology and UCLA,s Jonsson Comprehensive Cancer Center. ... up regulated or turned on in prostate cancer that ...
... PHILADELPHIA Molecular biologist Jonathan Brody, Ph.D., ... Goney, Ph.D., research assistant professor, and member of ... in the Department of Pathology, Anatomy and Cell ... University have been awarded a W.W. Smith Charitable ...
... blood "metabolomics" profile of smokers immediately after they ... in cell death, inflammation, and other forms of ... Cancer Center, part of Georgetown University Medical Center. ... the Ninth AACR Frontiers in Cancer Prevention Research ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Jefferson researchers receive W.W. Smith Charitable Trust 2Jefferson researchers receive W.W. Smith Charitable Trust 3Studying the metabolome of smokers, Lombardi researchers find early signs of damage 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and ... genomics, proteomics and drug development laboratories. ... of instrumentation to automate basic liquid ... Mini-Workstations are controlled with either Caliper's ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: